News

Novo Nordisk and Vivtex Corporation have announced a strategic partnership to develop next-generation oral biologic medicines targeting obesity, diabetes and related metabolic…
Read More...

IQVIA Holdings Inc. has entered into an agreement to acquire certain drug discovery services assets from Charles River Laboratories, a move designed to expand its early-stage research…
Read More...

Japanese industrial giant Asahi Kasei has agreed to acquire German biopharmaceutical firm Aicuris Anti-infective Cures AG for about €780 million (roughly $919 million), a deal aimed at…
Read More...

NorthX Biologics and Demeetra have announced a strategic collaboration aimed at streamlining biologics development and accelerating biotech companies’ progress toward investigational…
Read More...

Slate Medicines, Inc. has emerged from stealth with $130 million in Series A financing and the in-licensing of a promising migraine therapy, positioning the company to compete in the…
Read More...

GSK plc announced that ViiV Healthcare has reported positive 12-month interim results from its phase IIb EMBRACE study, highlighting the potential of an ultra long-acting HIV treatment…
Read More...

GSK plc has agreed to acquire 35Pharma Inc., a privately held Canadian biopharmaceutical company focused on protein-based therapeutics. The deal brings into GSK’s pipeline HS235, an…
Read More...

Gilead Sciences, Inc. has entered into a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion, strengthening its oncology and cell therapy…
Read More...

AbbVie has unveiled plans to invest $380 million to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois campus, expanding…
Read More...

The U.S. Food and Drug Administration has released a new draft guidance aimed at accelerating the development and approval of highly targeted, individualized therapies for patients with…
Read More...

AstraZeneca has secured U.S. approval for a new all-oral, fixed-duration treatment regimen for adults with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL),…
Read More...

The European Commission has announced a €225 million investment aimed at accelerating the development of next-generation influenza vaccines capable of providing broader protection…
Read More...

AbbVie has announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for the combination of VENCLEXTA® (venetoclax) and acalabrutinib…
Read More...

Clinical-stage biotech VivaMed BioPharma has entered into a strategic partnership with Syngene International, a global contract research, development and manufacturing organization…
Read More...

Merck & Co., Inc., known as MSD outside the United States and Canada, has entered into a major research and development agreement with Mayo Clinic to apply artificial intelligence…
Read More...

Novartis has announced positive topline results from its pivotal Phase III RemIND trial evaluating oral remibrutinib in patients with chronic inducible urticaria (CIndU), a condition…
Read More...

Johnson & Johnson has unveiled new data from its Phase 1b/2 OrigAMI-4 study, demonstrating that first-line treatment with investigational subcutaneous amivantamab and…
Read More...

Boehringer Ingelheim India Private Limited has signed a Memorandum of Understanding (MoU) with National Institute of Pharmaceutical Education and Research, Raebareli (NIPER Raebareli),…
Read More...

Catalent and S.Biomedics have entered into a strategic partnership to advance the development and manufacturing of TED-A9, an investigational allogeneic pluripotent stem cell-derived…
Read More...

Johnson & Johnson has announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, further…
Read More...